- Trial phase
- Filed/PMA (Not Approvable Letter received)
- Time to market
- Uncertain; the FDA rejected the current PMA application. NovoCure plans to meet with the FDA to discuss options that may not require additional clinical studies, but no timeline for a resubmission or potential approval has been established.
- Why 3/10
- Optune Mya's next hard catalyst is uncertain: the company plans to meet with the FDA after receiving a Not Approvable Letter today, but no date for that meeting or a resubmission has been set. The binary PMA decision has already passed with a negative outcome, so no near-term dated binary exists for this specific drug.
The FDA's Not Approvable Letter for Optune Mya removes a key pipeline catalyst. Watch for NovoCure's planned meeting with the FDA to see if a path forward emerges without additional clinical studies. Separately, the Dec 31, 2026 PDUFA for Optune Pax (a different device) in the same brain metastases indication remains a major upcoming binary for NVCR.
Price Chart
Executive Summary
Optune Mya is NovoCure's portable Tumor Treating Fields (TTFields) device being developed for brain metastases from non-small cell lung cancer. On November 9, 2026, the FDA issued a Not Approvable Letter for its Premarket Approval application, citing uncertainty around clinical benefit while raising no safety concerns. NovoCure plans to meet with the FDA to explore a path forward, but there is no assurance of eventual approval. The rejection removes a key pipeline catalyst for NVCR, though the company has other approved TTFields devices generating growing revenue and a separate Dec 31, 2026 PDUFA for Optune Pax in the same indication.
How It Works
Optune Mya is a portable, wearable device that delivers Tumor Treating Fields (TTFields), alternating electric fields applied non-invasively through arrays placed on the skin. These fields disrupt the electrical properties of cancer cells, interfering with their division and survival processes, leading to cell death while largely sparing healthy cells. It is a physical, non-pharmaceutical cancer therapy.
Trial Status
NovoCure submitted a Premarket Approval (PMA) application to the FDA for Optune Mya to treat brain metastases from non-small cell lung cancer following stereotactic radiation. On November 9, 2026, the FDA issued a Not Approvable Letter, determining that the clinical benefit data was insufficient for approval. The company plans to request a meeting with the FDA to discuss next steps.
The Two-Sided Case
Upcoming Catalysts
- FDA meeting to discuss path forward for Optune Mya (no date set)
- PDUFA date of December 31, 2026 for Optune Pax (a different device) for brain metastases from non-small cell lung cancer
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NovoCure Ltd 8-K NVCR ·Originating report